Preclinical assessment of the T-cell lymphoma drug bexarotene in motor neuron disease.

Project Details

StatusActive
Effective start/end date1/06/2431/05/27

Funding

  • Lifearc: £281,877.51
  • Lifearc: £257,971.96
  • Lifearc: £30,009.91